MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2025 International Congress

    The Cleveland Clinic-Virtual Home Environment (CC-VHE): A Reliable Way to Trigger Freezing of Gait in Parkinson’s disease

    A. Rosenfeldt, M. Miller Koop, A. Bazyk, V. Berki, S. Nagel, B. Walter, J. Liao, K. Baker, J. Alberts (Cleveland, USA)

    Objective: To describe the development, safety, and efficacy of the Cleveland Clinic-Virtual Home Environment (CC-VHE) in provoking freezing of gait (FOG) in Parkinson’s disease (PD).…
  • 2025 International Congress

    A personalized gait signature assay in Parkinson’s disease

    H. Babcock, J. Stephen, V. Vanderhorst (Boston, USA)

    Objective: To establish a personalized gait signature assay to inform on progression, phenotype and effects of intervention of gait abnormalities in PD. Background: Gait signatures…
  • 2025 International Congress

    Health Disparity in Rural Southern California

    A. Maleki, M. Tar, D. Tar (moreno valley, USA)

    Objective: To analyze the demographic and clinical characteristics of hispanic patients with Parkinson's disease in rural southern California Background: Parkinson’s disease (PD) is the second…
  • 2025 International Congress

    The Role of Knowledgeable Informants in the Early Detection of Parkinson’s Disease

    E. Trinh, K. Harrison, M. Korell, C. Meng, E. Brown, K. Comyns, X. Chen, M. Bock, L. Racelo, G. Stebbins, C. Tanner (San Francisco, USA)

    Objective: To investigate the reporting of changes observed by Knowledgeable Informants (KIs) and people with Parkinson’s disease (PwPD) prior to a Parkinson’s disease (PD) diagnosis.…
  • 2025 International Congress

    Parkinson’s Disease: Increased Presence of Neuropsychiatric Symptoms and Non-Motor Issues Drive Higher Medication Use and Costs

    S. Horn, E. Vaou, A. Parab, S. Wang, X. Pan, C. Yan, M. Shah, J. Jimenez-Shahed (San Antonio, USA)

    Objective: To compare neuropsychiatric disorders (NPsy), other non-motor symptoms (NMS), and associated medication use and costs in individuals with advanced Parkinson’s Disease (aPD) with those…
  • 2025 International Congress

    The influence of Caffeine intake on Type 2 Diabetes Mellitus mediated risk of Parkinson’s Disease.

    K. Mallavarapu, E. Tan (Singapore, Singapore)

    Objective: The objectives are to investigate if a diagnosis of Type 2 Diabetes Mellitus (T2DM) is associated with increased risk of developing Parkinson's Disease (PD)…
  • 2025 International Congress

    Deferiprone improves striatal dopamine by reducing neuroinflammation and oxidative stress in MPTP-induced mice model of Parkinson’s disease

    HSA. Olasore, JO. Faleti (Lagos, Nigeria)

    Objective: This study aimed to investigate the effect of deferiprone on the striatal DA, oxidative stress and neuroinflammation markers as well as motor deficits in…
  • 2025 International Congress

    Rescuing alpha-synuclein toxicity through neuron-specific enhancement of autophagy

    J. Chua, M. Farah, S. Tewari, A. Parvataneni, V. Dawson, T. Dawson (Baltimore, USA)

    Objective: In the present study, we aim to counteract regulatory and transcriptional modifiers of autophagy to enhance neuroprotective proteostasis and rescue alpha-synuclein (asyn) toxicity in…
  • 2025 International Congress

    Mathematical and Computational Modeling Prototype to Understand the Evolution of Parkinson’s disease using Four Differential Equations

    G. Sa, A. Rodrigues Tavares, M. Silva Bissaco (Mogi das Cruzes, Brazil)

    Objective: Apply four differential equations to generate projections considering the effect of dopamine on Parkinson’s disease progression, leading to the development of an initial prototype…
  • 2025 International Congress

    Comparison of MIBG Uptake in the Major Salivary Glands Between Rapid Eye Movement Sleep Behavior Disorder and Parkinson’s Disease

    J. Ebina, S. Mizumura, M. Shibukawa, J. Nagasawa, T. Hirayama, N. Ishii, Y. Kobayashi, A. Inaba, S. Orimo, O. Kano (Tokyo, Japan)

    Objective: This study aimed to evaluate 123I-metaiodobenzylguanidine (MIBG) uptake in the major salivary glands (MSG) in patients with rapid eye movement sleep behavior disorder (RBD)…
  • « Previous Page
  • 1
  • …
  • 159
  • 160
  • 161
  • 162
  • 163
  • …
  • 553
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley